ArticleFrontiers in endocrinology2023
Association of alpha-aminoadipic acid with cardiometabolic risk factors in healthy and high-risk individuals.
Article in Frontiers in endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 16 citations in OpenAlex.
- The consumption of animal products is associated with plasma levels of alpha-aminoadipic acid (2-AAA).Nutrition, metabolism, and cardiovascular diseases : NMCD · 2024Trial
- Metabolic pathways associated with cardiometabolic risk effects on cognition in middle-aged adults: the CARDIA study.Metabolomics : Official journal of the Metabolomic Society · 2026Article
- The Response of Alpha-Aminoadipic Acid (2-AAA) to Short Term Lysine Ingestion in Healthy Individuals.Endocrinology, diabetes & metabolism · 2026Article
- Association between dietary amino acid intake and the risk of metabolic dysfunction-associated steatotic liver disease.Journal of advanced research · 2026Article
- Plasma Lipid Metabolites Differentiate Metabolic From Viral Chronic Liver Disease.The Journal of infectious diseases · 2025Article
- Serum metabolites characterize hepatic phenotypes and reveal shared pathways: results from population-based imaging.Molecular medicine (Cambridge, Mass.) · 2025Article
- Integrated metabolomics and network pharmacology to investigate the effects of Yi-Qi-Xuan-Fei-Hua-Tan decoction for treating acute respiratory distress syndrome.Annals of medicine and surgery (2012) · 2025Article
- The Primacy of Adipose Tissue Gene Expression and Plasma Lipidome in Cardiometabolic Disease in Persons With HIV.The Journal of infectious diseases · 2025Observational
- Metabolite 2-aminoadipic acid: implications for metabolic disorders and therapeutic opportunities.Frontiers in pharmacology · 2025Review
- Circulating amino acid signature features urea cycle alterations associated with coronary artery disease.Scientific reports · 2024Observational
- Association of plant-based diet indexes with the metabolomic profile.Scientific reports · 2024Article
- Comparative Analysis of Serum Amino Acid Profiles in Patients with Myasthenia Gravis and Multiple Sclerosis.Journal of clinical medicine · 2024Article
- Prenatal Exposure to Chemical Mixtures and Metabolic Syndrome Risk in Children.JAMA network open · 2024Article
- Clinically relevant body composition phenotypes are associated with distinct circulating cytokine and metabolomic milieus in epithelial ovarian cancer patients.Frontiers in immunology · 2024Article
- Article
Corrections and comments
- Update of
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
Abstract
Introduction: Plasma levels of the metabolite alpha-aminoadipic acid (2-AAA) have been associated with risk of type 2 diabetes (T2D) and atherosclerosis. However, little is known about the relationship of 2-AAA to other cardiometabolic risk markers in pre-disease states, or in the setting of comorbid disease. Methods: We measured circulating 2-AAA using two methods in 1) a sample of 261 healthy individuals (2-AAA Study), and 2) in a sample of 134 persons comprising 110 individuals with treated HIV, with or without T2D, a population at high risk of metabolic disease and cardiovascular events despite suppression of circulating virus, and 24 individuals with T2D without HIV (HATIM Study). We examined associations between plasma 2-AAA and markers of cardiometabolic health within each cohort. Results and discussion: We observed differences in 2-AAA by sex and race in both cohorts, with higher levels observed in men compared with women, and in Asian compared with Black or white individuals (P<0.05). There was no significant difference in 2-AAA by HIV status within individuals with T2D in the HATIM Study. We confirmed associations between 2-AAA and dyslipidemia in both cohorts, where high 2-AAA associated with low HDL cholesterol (P<0.001) and high triglycerides (P<0.05). As expected, within the cohort of people with HIV, 2-AAA was higher in the setting of T2D compared to pre-diabetes or normoglycemia (P<0.001). 2-AAA was positively associated with body mass index (BMI) in the 2-AAA Study, and with waist circumference and measures of visceral fat volume in HATIM (all P<0.05). Further, 2-AAA associated with increased liver fat in persons with HIV (P<0.001). Our study confirms 2-AAA as a marker of cardiometabolic risk in both healthy individuals and those at high cardiometabolic risk, reveals relationships with adiposity and hepatic steatosis, and highlights important differences by sex and race. Further studies are warranted to establish molecular mechanisms linking 2-AAA to disease in other high-risk populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.